GSK/$GSK

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About GSK

In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.

Ticker

$GSK
Sector

Primary listing

NYSE

Employees

68,629

GSK Metrics

BasicAdvanced
$88B
39.06
$1.11
0.29
$1.58
3.93%

What the Analysts think about GSK

Analyst ratings (Buy, Hold, Sell) for GSK stock.

Bulls say / Bears say

GSK expects full-year sales and profit at the top of its 2025 guidance after Q2 results showed a 6% increase in turnover to nearly £8 billion and adjusted EPS of 46.5 pence, beating forecasts and demonstrating strong operations (Reuters)
The Jiangsu Hengrui deal gives GSK global rights to HRS-9821 for COPD, plus 11 early-stage programs in oncology, respiratory, immunology, and inflammation, with $500 million upfront and up to $12 billion in milestones. This meaningfully strengthens GSK’s pipeline (Reuters)
The EMA has accepted GSK’s application to expand its RSV vaccine Arexvy to adults 18 and over, potentially opening up a larger market in a field expected to reach $10 billion. This supports vaccine sales recovery, with a decision expected in H1 2026 (Reuters)
Analysts expect GSK will generate only £34 billion in revenue by 2031, which is 15% lower than its £40 billion target. This increases the chance of dilutive M&A deals or asset write-downs to make up the gap (Reuters Breakingviews)
Dolutegravir, which drives four of GSK’s HIV regimens and delivered over £5 billion in sales, will lose its U.S. patent protection in 2028. This will expose the group to significant generic competition and put pressure on cash flow (Reuters Breakingviews)
Dynavax’s experimental shingles vaccine Z-1018 produced an immune response comparable to Shingrix but caused injection-site reactions in just 12.5% of recipients, compared to Shingrix’s 52.6%. This poses a significant competitive threat to GSK’s leading vaccine (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 30 Sept 2025.

GSK Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

GSK Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $GSK

Sign up or log in to buy
Capital at risk
Market openADR

Upcoming events

FAQs